{"id":66358,"date":"2026-10-08T08:11:22","date_gmt":"2026-10-08T08:11:22","guid":{"rendered":"https:\/\/thepatientinvestor.com\/?p=66358"},"modified":"2026-10-08T08:34:39","modified_gmt":"2026-10-08T08:34:39","slug":"zurich-insurance-group-ag-zurn-update","status":"publish","type":"post","link":"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/","title":{"rendered":"Zurich Insurance Group AG (ZURN) – Update"},"content":{"rendered":"

Zurich Insurance Group AG (ZURN) announced it had completed its acquisition of Beazley plc on October 2, 2026.<\/p>\n

The $10.9 billion acquisition expands Zurich’s UK base, propelling it to a leading position in the UK Commercial segment and accelerating the group toward its goal of becoming a global leader in Specialty insurance.<\/p>\n

The combined Specialty division, with expected $15 billion in GWP, will be headquartered in London. Specialty has limited competition and enjoys higher margins than run-of-the-mill Property & Casualty (P&C). Zurich already has a formidable presence in Construction & Engineering, Energy, and Captives, writing $9 billion in annual gross written premiums (GWP). This is complemented by Beazley’s strengths in Cyber, Marine, E&S (excess and surplus lines), Political Risk, Fine Art & Specie (valuables), and Financial lines.<\/p>\n

The Beazley acquisition also propels the group to a leading position in Lloyd’s syndicates:<\/p>\n

“Joining Lloyd’s of London for the first time is an important step, giving us access to a unique platform for capital, product and service innovation, specialist underwriting and global reach.” ~ Zurich CEO Mario Greco<\/p><\/blockquote>\n

Zurich expects the acquisition to deliver $150 million in annual cost savings, $1 billion in capital savings, and incremental revenue growth opportunities of more than USD 1 billion per year.<\/p>\n

The acquisition is funded by $3.0 billion in cash, $2.9 billion in debt, and $5 billion in new equity.<\/p>\n

Financial targets for the 2025\u20132027 period are unchanged: Core EPS compound annual growth of >9%, Core RoE of >23%, and cash remittances of >USD 19 billion (subject to an SST floor of 160%).<\/p>\n

\"Zurich<\/p>\n

Zurich’s Swiss Solvency Test (SST) ratio reflects its strong capital position, estimated at 266% in Q2 2026, up from 259% at December 31, 2025. The acquisition is expected to lower the SST ratio to a still-strong 236% in Q3. The group is also expected to maintain its Aa rating from Moody’s despite a 3% increase in its leverage ratio.<\/p>\n

\"Moody's<\/p>\n

Investments<\/h2>\n

Zurich’s half-year financial report reflects total investments of $177 billion at market value. Equity exposure is 6.0%, hedge funds and private equity are 3.0%, while credit and private debt are 44% ($78 billion) of total investments.<\/p>\n

\"Zurich<\/p>\n

Stress tests estimate that a 20% fall in equities would have less impact than a 50-basis-point drop in interest rates, but we consider the 3% exposure to hedge funds and private equity as higher risk.<\/p>\n

\"Zurich<\/p>\n

Most of the $78 billion in credit and private debt is investment grade, except for 15% of Non-Financial Credit, 1% of Financial Credit, and 40% of Private Debt.<\/p>\n

\"Zurich<\/p>\n

Non-Financial Credit<\/h3>\n

Of the Non-Financial Credit, only 6% ($1.6 billion) is lending to Technology companies.<\/p>\n

\"Zurich<\/p>\n

Private Debt<\/h3>\n

Private Debt exposure of $10.1 billion is further broken down by sector and debt performance. Infrastructure and Real Estate loans have experienced no defaults. Senior Corporate Lending is mostly non-investment-grade, but its loss experience is better than that of low investment-grade (Ba) securities. Private placements are 97% investment-grade but have a slightly higher loss rate.<\/p>\n

Middle market loans are a potential vulnerability, with only 5% investment-grade, though the group says that over 80% of the $1.3 billion exposure is to European borrowers, and software exposure is low.<\/p>\n

\"Zurich<\/p>\n

Middle market loans, with only 5% investment-grade, are a potential vulnerability. However, over 80% of the $1.3 billion exposure is to European borrowers, and software exposure is low. The $1.6 billion investment in CLOs is AAA investment grade, with losses triggered only if underlying defaults exceed 40%.<\/p>\n

Most importantly, the group has immaterial exposure to business development companies (BDCs) and pooled investments in commingled funds. These categories have experienced higher default rates in the past 12 months.<\/p>\n

\"Zurich<\/p>\n

Chart<\/h2>\n

The monthly chart below (in Swiss Francs) shows a lengthy consolidation below CHF 600 since early 2025. A breakout that later respects the new support level at CHF 600 would offer a long-term target of CHF 750.<\/p>\n

\"Zurich<\/p>\n

Conclusion<\/h2>\n

We consider Zurich Insurance Group AG to be a well-run company with low investment risk. The Beazley acquisition will likely take time to settle. However,\u00a0 the group has an exemplary acquisition record, and the combination strengthens its long-term positioning as the leader in specialty insurance.<\/p>\n

We maintain our BUY rating for Zurich Insurance Group AG, which trades under the symbol ZURN on the Swiss SIX exchange. The stock also trades under the American Depositary Receipt (“ADR”) program, with the symbol ZURVY, at a ratio of 20 American Depositary Shares (“ADSs”) to 1 ordinary share.<\/p>\n

Acknowledgements<\/h4>\n

Morningstar: Zurich Is a Rare Structurally Advantaged Multiline Insurer With a Narrow Moat<\/a> (PDF)<\/p>\n","protected":false},"excerpt":{"rendered":"

Zurich Insurance Group AG (ZURN) announced it had completed its acquisition of Beazley plc on October 2, 2026. The $10.9 billion acquisition expands Zurich’s UK base, propelling it to a leading position in the UK Commercial segment and accelerating the group toward its goal of becoming a global leader in Specialty insurance. The combined Specialty … <\/p>\n

Continue reading “Zurich Insurance Group AG (ZURN) – Update”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3803],"tags":[7397],"class_list":["post-66358","post","type-post","status-publish","format-standard","hentry","category-pvt-international","tag-zurich-insurance-group-ag-zurn"],"yoast_head":"\nZurich Insurance Group AG (ZURN) - Update - the patient investor<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zurich Insurance Group AG (ZURN) - Update - the patient investor\" \/>\n<meta property=\"og:description\" content=\"Zurich Insurance Group AG (ZURN) announced it had completed its acquisition of Beazley plc on October 2, 2026. The $10.9 billion acquisition expands Zurich’s UK base, propelling it to a leading position in the UK Commercial segment and accelerating the group toward its goal of becoming a global leader in Specialty insurance. The combined Specialty … Continue reading "Zurich Insurance Group AG (ZURN) – Update"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/\" \/>\n<meta property=\"og:site_name\" content=\"the patient investor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61572934660810\" \/>\n<meta property=\"article:author\" content=\"https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-08T08:11:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-08T08:34:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.incrediblecharts.com\/images\/2026\/2026-10-05-zurn-targets.png\" \/>\n<meta name=\"author\" content=\"Colin Twiggs\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Colin Twiggs\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2026\\\/10\\\/08\\\/zurich-insurance-group-ag-zurn-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2026\\\/10\\\/08\\\/zurich-insurance-group-ag-zurn-update\\\/\"},\"author\":{\"name\":\"Colin Twiggs\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/person\\\/d42b18d516a80149d739845749ac6454\"},\"headline\":\"Zurich Insurance Group AG (ZURN) – Update\",\"datePublished\":\"2026-10-08T08:11:22+00:00\",\"dateModified\":\"2026-10-08T08:34:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2026\\\/10\\\/08\\\/zurich-insurance-group-ag-zurn-update\\\/\"},\"wordCount\":706,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2026\\\/10\\\/08\\\/zurich-insurance-group-ag-zurn-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2026\\\/2026-10-05-zurn-targets.png\",\"keywords\":[\"Zurich Insurance Group AG (ZURN)\"],\"articleSection\":[\"PVT International Portfolio\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2026\\\/10\\\/08\\\/zurich-insurance-group-ag-zurn-update\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2026\\\/10\\\/08\\\/zurich-insurance-group-ag-zurn-update\\\/\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2026\\\/10\\\/08\\\/zurich-insurance-group-ag-zurn-update\\\/\",\"name\":\"Zurich Insurance Group AG (ZURN) - Update - the patient investor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2026\\\/10\\\/08\\\/zurich-insurance-group-ag-zurn-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2026\\\/10\\\/08\\\/zurich-insurance-group-ag-zurn-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2026\\\/2026-10-05-zurn-targets.png\",\"datePublished\":\"2026-10-08T08:11:22+00:00\",\"dateModified\":\"2026-10-08T08:34:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2026\\\/10\\\/08\\\/zurich-insurance-group-ag-zurn-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2026\\\/10\\\/08\\\/zurich-insurance-group-ag-zurn-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2026\\\/10\\\/08\\\/zurich-insurance-group-ag-zurn-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2026\\\/2026-10-05-zurn-targets.png\",\"contentUrl\":\"https:\\\/\\\/www.incrediblecharts.com\\\/images\\\/2026\\\/2026-10-05-zurn-targets.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2026\\\/10\\\/08\\\/zurich-insurance-group-ag-zurn-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/thepatientinvestor.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zurich Insurance Group AG (ZURN) – Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#website\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/\",\"name\":\"The Patient Investor\",\"description\":\"Smart. Strategic. Unfiltered. \",\"publisher\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/thepatientinvestor.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\",\"name\":\"The Patient Investor Pty Ltd\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/thepatientinvestor.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/thepatientinvestor.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"width\":250,\"height\":250,\"caption\":\"The Patient Investor Pty Ltd\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61572934660810\",\"https:\\\/\\\/www.instagram.com\\\/colin_thepatientinvestor\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/person\\\/d42b18d516a80149d739845749ac6454\",\"name\":\"Colin Twiggs\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"caption\":\"Colin Twiggs\"},\"description\":\"Colin Twiggs is a former investment banker with almost 40 years of experience in financial markets. He founded PVT Capital (AFSL number 546090), which provides income and growth strategies to wholesale clients. Colin also co-founded Incredible Charts and writes the popular Patient Investor newsletter. Using a top-down approach, Colin identifies macro trends in the global economy and then combines fundamental and technical analysis to evaluate opportunities in sectors that stand to benefit. Focusing on interest rates and financial market liquidity as primary drivers of the economic cycle, he warned of the 2008\\\/2009 and 2020 bear markets well ahead of actual events.\",\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/people\\\/The-Patient-Investor\\\/61572934660810\\\/\",\"https:\\\/\\\/www.instagram.com\\\/colin_thepatientinvestor\",\"https:\\\/\\\/au.linkedin.com\\\/in\\\/colintwiggs\"],\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/author\\\/investor\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zurich Insurance Group AG (ZURN) - Update - the patient investor","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"Zurich Insurance Group AG (ZURN) - Update - the patient investor","og_description":"Zurich Insurance Group AG (ZURN) announced it had completed its acquisition of Beazley plc on October 2, 2026. The $10.9 billion acquisition expands Zurich’s UK base, propelling it to a leading position in the UK Commercial segment and accelerating the group toward its goal of becoming a global leader in Specialty insurance. The combined Specialty … Continue reading \"Zurich Insurance Group AG (ZURN) – Update\"","og_url":"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/","og_site_name":"the patient investor","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61572934660810","article_author":"https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/","article_published_time":"2026-10-08T08:11:22+00:00","article_modified_time":"2026-10-08T08:34:39+00:00","og_image":[{"url":"https:\/\/www.incrediblecharts.com\/images\/2026\/2026-10-05-zurn-targets.png","type":"","width":"","height":""}],"author":"Colin Twiggs","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Colin Twiggs","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/#article","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/"},"author":{"name":"Colin Twiggs","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/d42b18d516a80149d739845749ac6454"},"headline":"Zurich Insurance Group AG (ZURN) – Update","datePublished":"2026-10-08T08:11:22+00:00","dateModified":"2026-10-08T08:34:39+00:00","mainEntityOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/"},"wordCount":706,"commentCount":0,"publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"image":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incrediblecharts.com\/images\/2026\/2026-10-05-zurn-targets.png","keywords":["Zurich Insurance Group AG (ZURN)"],"articleSection":["PVT International Portfolio"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/","url":"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/","name":"Zurich Insurance Group AG (ZURN) - Update - the patient investor","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/#primaryimage"},"image":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.incrediblecharts.com\/images\/2026\/2026-10-05-zurn-targets.png","datePublished":"2026-10-08T08:11:22+00:00","dateModified":"2026-10-08T08:34:39+00:00","breadcrumb":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/#primaryimage","url":"https:\/\/www.incrediblecharts.com\/images\/2026\/2026-10-05-zurn-targets.png","contentUrl":"https:\/\/www.incrediblecharts.com\/images\/2026\/2026-10-05-zurn-targets.png"},{"@type":"BreadcrumbList","@id":"https:\/\/thepatientinvestor.com\/index.php\/2026\/10\/08\/zurich-insurance-group-ag-zurn-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thepatientinvestor.com\/"},{"@type":"ListItem","position":2,"name":"Zurich Insurance Group AG (ZURN) – Update"}]},{"@type":"WebSite","@id":"https:\/\/thepatientinvestor.com\/#website","url":"https:\/\/thepatientinvestor.com\/","name":"The Patient Investor","description":"Smart. Strategic. Unfiltered. ","publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thepatientinvestor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/thepatientinvestor.com\/#organization","name":"The Patient Investor Pty Ltd","url":"https:\/\/thepatientinvestor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","contentUrl":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","width":250,"height":250,"caption":"The Patient Investor Pty Ltd"},"image":{"@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61572934660810","https:\/\/www.instagram.com\/colin_thepatientinvestor"]},{"@type":"Person","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/d42b18d516a80149d739845749ac6454","name":"Colin Twiggs","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","caption":"Colin Twiggs"},"description":"Colin Twiggs is a former investment banker with almost 40 years of experience in financial markets. He founded PVT Capital (AFSL number 546090), which provides income and growth strategies to wholesale clients. Colin also co-founded Incredible Charts and writes the popular Patient Investor newsletter. Using a top-down approach, Colin identifies macro trends in the global economy and then combines fundamental and technical analysis to evaluate opportunities in sectors that stand to benefit. Focusing on interest rates and financial market liquidity as primary drivers of the economic cycle, he warned of the 2008\/2009 and 2020 bear markets well ahead of actual events.","sameAs":["https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/","https:\/\/www.instagram.com\/colin_thepatientinvestor","https:\/\/au.linkedin.com\/in\/colintwiggs"],"url":"https:\/\/thepatientinvestor.com\/index.php\/author\/investor\/"}]}},"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p9tQ4n-hgi","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":65407,"url":"https:\/\/thepatientinvestor.com\/index.php\/2026\/07\/25\/zurich-insurance-group-ag-adr-zurvy\/","url_meta":{"origin":66358,"position":0},"title":"Zurich Insurance Group AG (ADR: ZURVY)","author":"Colin Twiggs","date":"July 25, 2026","format":false,"excerpt":"Zurich Insurance Group AG\u00a0is one of the most successful European multiline insurers with over USD 60 billion of annual gross written premiums. Zurich writes business across both Life and non-Life insurance and also owns Farmers Management Services. Europe (EMEA) and North America are the strongest regions, contributing 56% and 41%\u2026","rel":"","context":"In "PVT International Portfolio"","block_context":{"text":"PVT International Portfolio","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/pvt-international\/"},"img":{"alt_text":"Zurich Insurance Group AG (ZURVY) Return on Assets & Return on Equity","src":"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-07-23-ZURVY-roe.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-07-23-ZURVY-roe.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-07-23-ZURVY-roe.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-07-23-ZURVY-roe.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-07-23-ZURVY-roe.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-07-23-ZURVY-roe.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":66103,"url":"https:\/\/thepatientinvestor.com\/index.php\/2026\/09\/24\/zurich-insurance-sticks-to-10-billion-private-credit-exposure\/","url_meta":{"origin":66358,"position":1},"title":"Zurich Insurance Sticks to $10 Billion Private Credit Exposure","author":"Colin Twiggs","date":"September 24, 2026","format":false,"excerpt":"Zurich Insurance Sticks to $10 Billion Private Credit Exposure From Investrends.ch May 13, 2026, 2:58 PM (translated from German) Zurich Insurance remains unconcerned regarding its exposure to the private credit market, which is currently under pressure. The group sees \"no signs of impairments or quality deterioration\" in its private corporate\u2026","rel":"","context":"In "PVT International Portfolio"","block_context":{"text":"PVT International Portfolio","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/pvt-international\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":66102,"url":"https:\/\/thepatientinvestor.com\/index.php\/2026\/09\/29\/insurance-private-credit-exposure\/","url_meta":{"origin":66358,"position":2},"title":"Insurance – Private Credit Exposure","author":"Colin Twiggs","date":"September 29, 2026","format":false,"excerpt":"Allocation to private credit varies greatly amongst insurers in our coverage. Coverage of insurers' private credit exposure is scant, and we have had to scour the internet to identify insurers' exposure. International (Figures are in USD unless otherwise stated) Symbol Exch Name Industry Market Cap Private Credit Exposure % of\u2026","rel":"","context":"In "PVT Australian Portfolio"","block_context":{"text":"PVT Australian Portfolio","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/pvt-australia\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":65366,"url":"https:\/\/thepatientinvestor.com\/index.php\/2026\/07\/21\/qbe-insurance-group-ltd-qbe\/","url_meta":{"origin":66358,"position":3},"title":"QBE Insurance Group Ltd (QBE)","author":"Colin Twiggs","date":"July 21, 2026","format":false,"excerpt":"QBE Insurance Group Ltd (QBE) is an international property and casualty insurance company with USD 24 billion of annual gross written premiums. It writes about 25% of its annual premiums in its home region of Australia and New Zealand and 25% in North America. Commercial and specialty insurance lines make\u2026","rel":"","context":"In "PVT Australian Portfolio"","block_context":{"text":"PVT Australian Portfolio","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/pvt-australia\/"},"img":{"alt_text":"QBE Insurance Group Ltd (QBE) Return on Assets & Return on Equity","src":"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-07-20-QBE-roe.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-07-20-QBE-roe.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-07-20-QBE-roe.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-07-20-QBE-roe.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-07-20-QBE-roe.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-07-20-QBE-roe.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":65405,"url":"https:\/\/thepatientinvestor.com\/index.php\/2026\/07\/24\/allianz-se-alizf\/","url_meta":{"origin":66358,"position":4},"title":"Allianz SE (ALIZF)","author":"Colin Twiggs","date":"July 24, 2026","format":false,"excerpt":"30 June 2026 Allianz SE (ALIZF.OTC) provides property-casualty insurance, life\/health insurance, and asset management products and services worldwide. The company's Property-Casualty segment offers motor liability, accident, fire and property, general liability, credit, and travel insurance, as well as assistance services, to private and corporate customers. Its Life\/Health segment provides a\u2026","rel":"","context":"In "PVT International Portfolio"","block_context":{"text":"PVT International Portfolio","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/pvt-international\/"},"img":{"alt_text":"Allianz (ALIZF) Revenue & Profit Margins","src":"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-06-27-ALIZF-sales-margins.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-06-27-ALIZF-sales-margins.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-06-27-ALIZF-sales-margins.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-06-27-ALIZF-sales-margins.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-06-27-ALIZF-sales-margins.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/www.incrediblecharts.com\/images\/2026\/2026-06-27-ALIZF-sales-margins.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":18121,"url":"https:\/\/thepatientinvestor.com\/index.php\/2019\/04\/15\/computershare-ltd-cpu-4\/","url_meta":{"origin":66358,"position":5},"title":"Computershare Ltd (CPU)","author":"Colin Twiggs","date":"April 15, 2019","format":false,"excerpt":"Stock: Computershare Ltd Exchange: ASX Symbol: CPU Date: April 15, 2019 Latest price: $17.50 AUD Market Cap: $9.49 bn Fair Value Estimate: $17.50 Forward P\/E: 16.8 Fair Value Payback: 12 Years Financial Y\/E: 30 June Recommendation: Accumulate Sector: Technology Industry: Information Technology Investment Theme: Dividends & Growth Structural Trends: none\u2026","rel":"","context":"In "PVT Australian Portfolio"","block_context":{"text":"PVT Australian Portfolio","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/pvt-australia\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/66358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/comments?post=66358"}],"version-history":[{"count":3,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/66358\/revisions"}],"predecessor-version":[{"id":66365,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/66358\/revisions\/66365"}],"wp:attachment":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/media?parent=66358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/categories?post=66358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/tags?post=66358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}